Dexamethasone Suppresses IL-33-exacerbated Malignant Phenotype of U87MG Glioblastoma Cells via NF-κB and MAPK Signaling Pathways.
Jie AiYinhua WengLiyan JiangChao LiuHongbo LiuHuoying ChenPublished in: Anti-cancer agents in medicinal chemistry (2024)
DEX inhibited the production and tumor-promoting function of IL-33. Whether DEX can benefit GBM patients remains controversial. Our results suggest that GBM patients with high IL-33 expression may benefit from DEX treatment and deserve further investigation.
Keyphrases
- signaling pathway
- induced apoptosis
- pi k akt
- end stage renal disease
- cell cycle arrest
- ejection fraction
- poor prognosis
- newly diagnosed
- oxidative stress
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- low dose
- patient reported outcomes
- long non coding rna
- toll like receptor
- nuclear factor
- patient reported